All News
#EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 :
⭐️⬇️ mortality and ventilation at day 29
⭐️61% reduction in death (HR 0.39)
⭐️No drug related SAEs, no dose-related AEs
@Rheumnow https://t.co/9UOi3xF7Re
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 LB0002 #COVID vax safety in RMD
⭐️78% received Pfizer, 16% Astra Zeneca
⭐️5% of pts flares, 1.2% severe flares
⭐️31% had vax side effects, 0.1% severe AEs
Side effect profile similar to gen population. Good data for uncertain patients!
@RheumNow @rheum_covid https://t.co/PGZcph9Mu6
Eric Dein ejdein1 ( View Tweet)
What’s the biggest reason for vaccine hesitancy in your patients? @RheumNow #EULAR2021
Eric Dein ejdein1 ( View Tweet)
#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel
⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls
⭐️RTX lowest seropos of 39%, related to time of infusion
⭐️⬇️ with GC, ABA, MMF
⭐️ MTX not seen to significantly ⬇️
@RheumNow @rheum_covid
Eric Dein ejdein1 ( View Tweet)
Even when we go outright looking for COVID vaccine-related problems in rheum disease patients, we really don't find much.
Get your rheumatology patients vaccinated!
reassuring from @eular_org COVAX registry, thanks to all involved! @pedrommcmachado LB0002 #EULAR2021 @RheumNow https://t.co/mIBeglQ5KS
David Liew drdavidliew ( View Tweet)
COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including:
demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59
Aurelie Najm AurelieRheumo ( View Tweet)
Presenting now at #EULAR2021
#COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study
https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has worse outcomes but clusters racially (⬇️ by skin tone) & seems related to SES. But perhaps adding vit D can help immune system & be anti-inflammatory #EULAR2021 @RheumNow POS0100 https://t.co/TEf52bLs0i
Janet Pope Janetbirdope ( View Tweet)
Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patients with COVID. Gradient boosting machine had 81% sensitivity to predict ARDS from baseline data @RheumNow #EULAR2021 Abstr#OP0288 https://t.co/tHlPzeX9He
Richard Conway RichardPAConway ( View Tweet)
Poorer outcomes with #JAKi in pts who get #SARSCoV2 but ? related to line of therapy - worse off if 2nd line advanced Rx in RA vs 1st line? JAKi has short half life so it washes out? And..#baricitinib added to #remdesivir improves outcomes NEJM @RheumNow #EULAR2021 #OP0006 Dunno! https://t.co/583z6Mlw3y
Janet Pope Janetbirdope ( View Tweet)
Presentation 3480 at #EULAR2021. Your patient is on CellCept, has negative COVID spike IgG and IgM antibodies after vaccination with mRNA vaccination x2. What do you counsel on this test? @RheumNow
Eric Dein ejdein1 ( View Tweet)
#Digital #rheumatology in the era of #COVID-19: evidently increasing inclination of patients and physicians to use digital health apps for recording data- as informed by a national survey by @JK77775 and colleagues #EULAR2021 @ARD_BMJ https://t.co/Uo60qZurhG
Latika LatikaGupta_ ( View Tweet)
Our SLR on pathogenesis of SARS-CoV-2 Main findings: TH1 cytokines and IL-6 associated w/ severe COVID19 and fatal outcomes. ⬆️ classical blood monocytes and polyfunctional T cells. Impaired IFN response associated w/ poor outcomes. #POS0052 @Rheumnow #EULAR2021 @alessia_alunno https://t.co/PGph5IRBkX
Aurelie Najm AurelieRheumo ( View Tweet)
Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006
Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO
Paul Studenic Stiddyo ( View Tweet)
Result from the #EULAR2021 recommendations on management of RMD in COVID update SLR: No evidence that people with RMDs present an increased risk of contracting COVID19, consistent with the initial Recos. @RheumNow https://t.co/2Q0s3ZKJOP
Aurelie Najm AurelieRheumo ( View Tweet)
@jeffsparks knocking it out of the park presenting our findings on b/tsDMARD associations with COVID-19 outcomes @eular_org @EULAR_Press check out our full paper just published in @ARD_BMJ https://t.co/jcA1LN45R3
Zach Wallace zach_wallace_md ( View Tweet)
Abs#OP0009 presents 8 min web-based video for COVID vax education sent via text message. 76% more likely to get vax. #EULAR2021. @RheumNow. Pts need to hear from their rheumatologists our thoughts on vax, ideally in person, but phone is great outreach https://t.co/aimGBufYpe
Eric Dein ejdein1 ( View Tweet)
Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021.
⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow
Eric Dein ejdein1 ( View Tweet)
I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf
Richard Conway RichardPAConway ( View Tweet)
#EULAR2021 recommendations: RMDs face no more risk of contracting COVID-19, no current evidence of worse prognosis. Do you tell patients similar stats? @RheumNow
Eric Dein ejdein1 ( View Tweet)